176 related articles for article (PubMed ID: 22104460)
1. Intensive glycemic control and cardiovascular disease: are there patients who may benefit?
Chokrungvaranon N; Deer J; Reaven PD
Postgrad Med; 2011 Nov; 123(6):114-23. PubMed ID: 22104460
[TBL] [Abstract][Full Text] [Related]
2. Intensive glycemic control and cardiovascular disease: an update.
Brown A; Reynolds LR; Bruemmer D
Nat Rev Cardiol; 2010 Jul; 7(7):369-75. PubMed ID: 20404853
[TBL] [Abstract][Full Text] [Related]
3. What matters in ADVANCE and ADVANCE-ON.
Hamet P
Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
[TBL] [Abstract][Full Text] [Related]
4. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
Tian J; Ohkuma T; Cooper M; Harrap S; Mancia G; Poulter N; Wang JG; Zoungas S; Woodward M; Chalmers J
Diabetes Care; 2020 Jun; 43(6):1293-1299. PubMed ID: 32193249
[TBL] [Abstract][Full Text] [Related]
5. Treating diabetes today with gliclazide MR: a matter of numbers.
Avogaro A
Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():14-9. PubMed ID: 22118706
[TBL] [Abstract][Full Text] [Related]
6. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
Dailey G
Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
[TBL] [Abstract][Full Text] [Related]
7. Intensive glucose control and cardiovascular outcomes in type 2 diabetes.
Macisaac RJ; Jerums G
Heart Lung Circ; 2011 Oct; 20(10):647-54. PubMed ID: 20807681
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.
Meier M; Hummel M
Vasc Health Risk Manag; 2009; 5():859-71. PubMed ID: 19898642
[TBL] [Abstract][Full Text] [Related]
9. Glucose supply and insulin demand dynamics of antidiabetic agents.
Monte SV; Schentag JJ; Adelman MH; Paladino JA
J Diabetes Sci Technol; 2010 Mar; 4(2):365-81. PubMed ID: 20307399
[TBL] [Abstract][Full Text] [Related]
10. Intensive glycaemic control in type 2 diabetes mellitus: does it improve cardiovascular outcomes?
Reddy SV; Bhatia E
Natl Med J India; 2011; 24(1):21-7. PubMed ID: 21608354
[TBL] [Abstract][Full Text] [Related]
11. Characterization of cardiovascular outcomes in a type 2 diabetes glucose supply and insulin demand model.
Monte SV; Schentag JJ; Adelman MH; Paladino JA
J Diabetes Sci Technol; 2010 Mar; 4(2):382-90. PubMed ID: 20307400
[TBL] [Abstract][Full Text] [Related]
12. [Current controversies in glycemic control targets. What do the results of the latest clinical trials tell us about the approach to type 2 diabetes mellitus?].
Mauricio D; Rius F
Med Clin (Barc); 2010 Sep; 135 Suppl 2():2-5. PubMed ID: 21420530
[TBL] [Abstract][Full Text] [Related]
13. Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
van der Leeuw J; Visseren FL; Woodward M; van der Graaf Y; Grobbee DE; Harrap S; Heller S; Mancia G; Marre M; Poulter N; Zoungas S; Chalmers J
Diabetologia; 2016 Dec; 59(12):2603-2612. PubMed ID: 27586250
[TBL] [Abstract][Full Text] [Related]
14. Antidiabetic agents and cardiovascular risk in type 2 diabetes.
Zarich SW
Nat Rev Endocrinol; 2009 Sep; 5(9):500-6. PubMed ID: 19636325
[TBL] [Abstract][Full Text] [Related]
15. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials.
Ismail-Beigi F; Moghissi E; Tiktin M; Hirsch IB; Inzucchi SE; Genuth S
Ann Intern Med; 2011 Apr; 154(8):554-9. PubMed ID: 21502652
[TBL] [Abstract][Full Text] [Related]
16. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus.
Kirkman MS; Mahmud H; Korytkowski MT
Endocrinol Metab Clin North Am; 2018 Mar; 47(1):81-96. PubMed ID: 29407058
[TBL] [Abstract][Full Text] [Related]
17. Glycemic control and cardiovascular disease: what's a doctor to do?
Kishore P; Kim SH; Crandall JP
Curr Diab Rep; 2012 Jun; 12(3):255-64. PubMed ID: 22467273
[TBL] [Abstract][Full Text] [Related]
18. Type 2 diabetes and cardiovascular disease: what next?
Joseph JJ; Golden SH
Curr Opin Endocrinol Diabetes Obes; 2014 Apr; 21(2):109-20. PubMed ID: 24569552
[TBL] [Abstract][Full Text] [Related]
19. [Hypoglycemia and cardiovascular risk].
Avogaro A
G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):4S-12S. PubMed ID: 25623545
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation.
J Hypertens Suppl; 2001 Nov; 19(4):S21-8. PubMed ID: 11848259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
